2024
ZFYVE21 promotes endothelial nitric oxide signaling and vascular barrier function in the kidney during aging
Jiang Q, Song G, He L, Li X, Jiang B, Wang Q, Wang S, Kim C, Barkestani M, Lopez R, Fan M, Wanniarachchi K, Quaranta M, Tian X, Mani A, Gonzalez A, Goodwin J, Sessa W, Ishibe S, Jane-Wit D. ZFYVE21 promotes endothelial nitric oxide signaling and vascular barrier function in the kidney during aging. Kidney International 2024, 106: 419-432. PMID: 38797325, PMCID: PMC11343665, DOI: 10.1016/j.kint.2024.05.007.Peer-Reviewed Original ResearchVascular barrier functionEndothelial cellsReduced endothelial nitric oxideRegulator of vascular barrier functionEndothelial nitric oxide signalingENOS activityEndosome-associated proteinsBarrier functionKidney organ culturesEndothelial nitric oxideAkt-dependent mannerNitric oxide donorGTPase Rab5Nitric oxide signalingZFYVE21Live cell imagingKidney insufficiencyReporter miceTrafficking mechanismsAccelerated aging phenotypeKnockout miceInterstitial edemaKidney functionVesicular populationOxide donor
2000
The HMG-CoA reductase inhibitor simvastatin activates the protein kinase Akt and promotes angiogenesis in normocholesterolemic animals.
Kureishi Y, Luo Z, Shiojima I, Bialik A, Fulton D, Lefer D, Sessa W, Walsh K. The HMG-CoA reductase inhibitor simvastatin activates the protein kinase Akt and promotes angiogenesis in normocholesterolemic animals. Nature Medicine 2000, 6: 1004-1010. PMID: 10973320, PMCID: PMC2828689, DOI: 10.1038/79510.Peer-Reviewed Original ResearchConceptsProtein kinase Akt/PKBKinase Akt/PKBProtein kinase AktAkt/PKBAkt-dependent mannerVascular structure formationActivation of AktKinase AktVascular endothelial growth factor treatmentEnhanced phosphorylationBlood vessel growthNew blood vessel growthAktGrowth factor treatmentVessel growthEndothelial cellsEndothelial nitric oxide synthaseRecent studiesHMG-CoA reductase inhibitor simvastatinAngiogenesisPKBFactor treatmentPhosphorylationReductase inhibitor simvastatinApoptosis